Affordable Access

Access to the full text

Doxorubicin Cardiotoxicity: Pathophysiology Updates

Authors
  • Hoeger, Christopher W.1, 2
  • Turissini, Cole1
  • Asnani, Aarti1, 2
  • 1 Beth Israel Deaconess Medical Center, 3 Blackfan Circle, CLS-911, Boston, MA, 02115, USA , Boston (United States)
  • 2 Harvard Medical School, Boston, MA, USA , Boston (United States)
Type
Published Article
Journal
Current Treatment Options in Cardiovascular Medicine
Publisher
Springer US
Publication Date
Oct 14, 2020
Volume
22
Issue
11
Identifiers
DOI: 10.1007/s11936-020-00842-w
Source
Springer Nature
Keywords
License
Yellow

Abstract

Purpose of reviewDoxorubicin has long been known to cause cardiotoxicity, yet our understanding of its pathophysiologic mechanisms remains incomplete. This review aims to update readers on the most recent evidence supporting candidate mechanisms and proposed treatments for doxorubicin cardiotoxicity.Recent findingsDoxorubicin causes cardiotoxicity via traditional mechanisms, such as oxidative stress, DNA and mitochondrial damage, and iron overload, as well as through novel pathways such as autophagy and CYP1 induction. The relative importance of each pathway and how these pathways interact with each other is not well-understood. Novel approaches to cardioprotection are needed.SummaryNovel mechanisms of doxorubicin cardiotoxicity represent exciting opportunities for prevention and treatment of this entity. Further studies are needed to translate recent findings into clinical use.

Report this publication

Statistics

Seen <100 times